Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01574703




Registration number
NCT01574703
Ethics application status
Date submitted
6/04/2012
Date registered
10/04/2012
Date last updated
29/12/2016

Titles & IDs
Public title
Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.
Scientific title
A Phase 4, Non-treatment Follow-up For Cardiac Assessments Following Use Of Smoking Cessation Treatments In Subjects With And Without A History Of Psychiatric Disorders
Secondary ID [1] 0 0
2011-005513-37
Secondary ID [2] 0 0
A3051148
Universal Trial Number (UTN)
Trial acronym
CATS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Smoking Cessation 0 0
Condition category
Condition code
Mental Health 0 0 0 0
Studies of normal psychology, cognitive function and behaviour

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - placebo
Treatment: Drugs - varenicline tartrate
Treatment: Drugs - bupropion hydrochloride
Treatment: Drugs - Nicotine Replacement Therapy Patch

Experimental: placebo -

Experimental: varenicline -

Experimental: bupropion -

Experimental: Nicotine Replacement Therapy Patch -


Treatment: Drugs: placebo
All dosing to have taken place per study A3051123

Treatment: Drugs: varenicline tartrate
All dosing to have taken place per study A3051123

Treatment: Drugs: bupropion hydrochloride
All dosing to have taken place per study A3051123

Treatment: Drugs: Nicotine Replacement Therapy Patch
All dosing to have taken place per study A3051123
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to Occurrence of Major Adverse Cardiovascular Event (MACE) During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.
Timepoint [1] 0 0
Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).
Secondary outcome [1] 0 0
Time to MACE up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.
Timepoint [1] 0 0
Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days.
Secondary outcome [2] 0 0
Time to MACE Until the End of Study NCT01574703.
Timepoint [2] 0 0
Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).
Secondary outcome [3] 0 0
Incidence of MACE Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.
Timepoint [3] 0 0
Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).
Secondary outcome [4] 0 0
Incidence of MACE + Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.
Timepoint [4] 0 0
Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).
Secondary outcome [5] 0 0
Incidence of MACE Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.
Timepoint [5] 0 0
Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days follow-up.
Secondary outcome [6] 0 0
Incidence of MACE+ Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.
Timepoint [6] 0 0
Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days follow-up.
Secondary outcome [7] 0 0
Incidence of MACE Assessed Until End of Study NCT01574703.
Timepoint [7] 0 0
Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).
Secondary outcome [8] 0 0
Incidence of MACE+ Assessed Until End of Study NCT01574703.
Timepoint [8] 0 0
Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).

Eligibility
Key inclusion criteria
- Subjects will be eligible if they were randomized to study A3051123.
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- Participation in study A3051123 ceased (ie, withdrew consent, lost to follow-up, etc)
prior to final visit of study A3051123.

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/05/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/07/2015
Sample size
Target
Accrual to date
Final
4595
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Monash Alfred Psychiatry Research Centre - Melbourne
Recruitment postcode(s) [1] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Idaho
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Louisiana
Country [13] 0 0
United States of America
State/province [13] 0 0
Maine
Country [14] 0 0
United States of America
State/province [14] 0 0
Massachusetts
Country [15] 0 0
United States of America
State/province [15] 0 0
Minnesota
Country [16] 0 0
United States of America
State/province [16] 0 0
Mississippi
Country [17] 0 0
United States of America
State/province [17] 0 0
Missouri
Country [18] 0 0
United States of America
State/province [18] 0 0
New Jersey
Country [19] 0 0
United States of America
State/province [19] 0 0
New York
Country [20] 0 0
United States of America
State/province [20] 0 0
North Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Ohio
Country [22] 0 0
United States of America
State/province [22] 0 0
Oregon
Country [23] 0 0
United States of America
State/province [23] 0 0
Pennsylvania
Country [24] 0 0
United States of America
State/province [24] 0 0
Rhode Island
Country [25] 0 0
United States of America
State/province [25] 0 0
South Carolina
Country [26] 0 0
United States of America
State/province [26] 0 0
Tennessee
Country [27] 0 0
United States of America
State/province [27] 0 0
Texas
Country [28] 0 0
United States of America
State/province [28] 0 0
Virginia
Country [29] 0 0
Argentina
State/province [29] 0 0
Buenos Aires
Country [30] 0 0
Argentina
State/province [30] 0 0
Capital Federal
Country [31] 0 0
Brazil
State/province [31] 0 0
RS
Country [32] 0 0
Brazil
State/province [32] 0 0
São Paulo
Country [33] 0 0
Brazil
State/province [33] 0 0
Sao Paulo
Country [34] 0 0
Bulgaria
State/province [34] 0 0
Bourgas
Country [35] 0 0
Bulgaria
State/province [35] 0 0
Kazanlak
Country [36] 0 0
Bulgaria
State/province [36] 0 0
Novi Iskar
Country [37] 0 0
Bulgaria
State/province [37] 0 0
Pleven
Country [38] 0 0
Bulgaria
State/province [38] 0 0
Plovdiv
Country [39] 0 0
Bulgaria
State/province [39] 0 0
Ruse
Country [40] 0 0
Bulgaria
State/province [40] 0 0
Sofia
Country [41] 0 0
Bulgaria
State/province [41] 0 0
Troyan
Country [42] 0 0
Canada
State/province [42] 0 0
Ontario
Country [43] 0 0
Canada
State/province [43] 0 0
Quebec
Country [44] 0 0
Chile
State/province [44] 0 0
Maule
Country [45] 0 0
Chile
State/province [45] 0 0
Valparaiso, V Region
Country [46] 0 0
Denmark
State/province [46] 0 0
Ballerup
Country [47] 0 0
Denmark
State/province [47] 0 0
Vejle
Country [48] 0 0
Finland
State/province [48] 0 0
Espoo
Country [49] 0 0
Finland
State/province [49] 0 0
Kuopio
Country [50] 0 0
Finland
State/province [50] 0 0
Nummela
Country [51] 0 0
Finland
State/province [51] 0 0
Oulu
Country [52] 0 0
Finland
State/province [52] 0 0
Pori
Country [53] 0 0
Finland
State/province [53] 0 0
Turku
Country [54] 0 0
Germany
State/province [54] 0 0
Baden-wuerttemberg
Country [55] 0 0
Germany
State/province [55] 0 0
Bayern
Country [56] 0 0
Germany
State/province [56] 0 0
Berlin
Country [57] 0 0
Germany
State/province [57] 0 0
Hamburg
Country [58] 0 0
Germany
State/province [58] 0 0
Leipzig
Country [59] 0 0
Germany
State/province [59] 0 0
Tuebingen
Country [60] 0 0
Mexico
State/province [60] 0 0
Mexico Df
Country [61] 0 0
Mexico
State/province [61] 0 0
Nuevo Leon
Country [62] 0 0
New Zealand
State/province [62] 0 0
Rotorua
Country [63] 0 0
Russian Federation
State/province [63] 0 0
Moscow
Country [64] 0 0
Russian Federation
State/province [64] 0 0
Nizhni Novgorod
Country [65] 0 0
Russian Federation
State/province [65] 0 0
Saint Petersburg
Country [66] 0 0
Russian Federation
State/province [66] 0 0
St. Petersburg
Country [67] 0 0
Slovakia
State/province [67] 0 0
Bratislava
Country [68] 0 0
Slovakia
State/province [68] 0 0
Levice
Country [69] 0 0
Slovakia
State/province [69] 0 0
Rimavska Sobota
Country [70] 0 0
Slovakia
State/province [70] 0 0
Roznava
Country [71] 0 0
South Africa
State/province [71] 0 0
Cape Town
Country [72] 0 0
South Africa
State/province [72] 0 0
Gauteng
Country [73] 0 0
South Africa
State/province [73] 0 0
Kwa-zulu Natal, South Africa
Country [74] 0 0
South Africa
State/province [74] 0 0
Kwazulu Natal
Country [75] 0 0
South Africa
State/province [75] 0 0
Western Cape
Country [76] 0 0
Spain
State/province [76] 0 0
Barcelona
Country [77] 0 0
Spain
State/province [77] 0 0
Caceres
Country [78] 0 0
Spain
State/province [78] 0 0
Madrid
Country [79] 0 0
Spain
State/province [79] 0 0
Zaragoza

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Non-treatment extension to study A3051123, aimed at collecting data on cardiovascular safety
for all participants in the A3051123 trial for an additional 28 weeks, allowing for a total
of 52 weeks of cardiovascular safety data collection.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01574703
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01574703